Conquering Diseases

Study Of A Reduction In Chemotherapy Drugs For Breast Cancer


Seeking men and women with HER2-positive breast cancer for a study comparing the usual multi-drug chemotherapy to a single chemotherapy drug and HER-2 therapy.


Participants in this study will receive 12 weeks of chemotherapy with a single drug and HER-2 therapy before surgery. Following successful surgery to remove the cancer, patients would continue to receive HER-2 therapy for a year and any other radiation and/or hormonal therapy advised by their doctor.

What we're hoping for

We are studying whether treatment with HER-2 therapy would allow for a reduction in the number of chemotherapy drugs needed to treat HER-2 positive breast cancer.

Additional Information Identifier: NCT04266249

 Principal Investigator

Kathryn  Edmiston, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655